Dexasone
B-Cell Non-Hodgkin Lymphoma
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Mwanasha Merrill, MD
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07588698CT.gov Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07097363CT.gov Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT06723457CT.gov Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05991388CT.gov A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
NCT06230224CT.gov A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05615636CT.gov A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | — | Recruiting | — | — | — |
NCT05476770CT.gov Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | — | Recruiting | — | — | — |
NCT04635683CT.gov Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT04792502CT.gov Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | — | Recruiting | — | — | — |
NCT05797948CT.gov GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Unknown | — | — | — |
Show 25 more trialsShow fewer
NCT05518383CT.gov B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | — | Recruiting | — | — | — |
NCT05201248CT.gov A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04882163CT.gov Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | — | Withdrawn | — | — | — |
NCT05016947CT.gov Venetoclax Plus Inotuzumab for B-ALL | — | Active Not Recruiting | — | — | — |
NCT05014100CT.gov Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma | — | Unknown | — | — | — |
NCT04578600CT.gov CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | — | Completed | — | — | — |
NCT04447716CT.gov An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment | — | Active Not Recruiting | — | — | — |
NCT04161248CT.gov Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03373019CT.gov Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | — | Unknown | — | — | — |
NCT03019640CT.gov Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT03114865CT.gov A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | — | Active Not Recruiting | — | — | — |
NCT03206671CT.gov Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents | — | Active Not Recruiting | — | — | — |
NCT03105596CT.gov Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) | — | Unknown | — | — | — |
NCT02992522CT.gov Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02898259CT.gov Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma | — | Terminated | — | — | — |
NCT02741388CT.gov A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP | — | Completed | — | — | — |
NCT02208037CT.gov Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | — | Completed | — | — | — |
NCT02055924CT.gov Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas | — | Terminated | — | — | — |
NCT02071888CT.gov Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | — | Completed | — | — | — |
NCT01919619CT.gov Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | — | Completed | — | — | — |
NCT01744912CT.gov Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | — | Terminated | — | — | — |
NCT01695941CT.gov Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma | — | Active Not Recruiting | — | — | — |
NCT00992446CT.gov Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01055496CT.gov Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma | — | Completed | — | — | — |
NCT00379574CT.gov Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Non-Hodgkin Lymphoma
+42 more in the B-Cell Non-Hodgkin Lymphoma cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Dexasone in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/dexasone-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →